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Abstract
Background: Clear cell renal cell carcinoma, a solid growing tumor, is the most common tumor in human kidney.
Evaluating the usefulness of b-galactoside binding galectin-3 as a diagnostic marker for this type of cancer could
open avenues for preventive and therapeutic strategies by employing specific inhibitors of the lectin. To study a
putative correlation between the extent of galectin-3 and the development of clear cell renal cell carcinoma, we
monitored the quantity and distribution of this lectin in tissue samples from 39 patients.
Methods: Galectin-3 concentrations in normal, intermediate and tumor tissues were examined by
immunofluorescence microscopy and on immunoblots with antibodies directed against galectin-3 and renal
control proteins. The cell nuclei were isolated to determine quantities of galectin-3 that were transferred into this
compartment in normal or tumor samples.
Results: Immunofluorescence data revealed a mosaic pattern of galectin-3 expression in collecting ducts and distal
tubules of normal kidney. Galectin-3 expression was significantly increased in 79% of tumor samples as compared
to normal tissues. Furthermore, we observed an increase in nuclear translocation of the lectin in tumor tissues.
Conclusions: Our data indicate that changes in the cellular level of galectin-3 correlate with the development of
clear cell renal cell carcinoma, which is in line with previously published data on this specific type of tumor. In
most of these studies the lectin tends to be highly expressed in tumor tissues. Furthermore, this study suggests
that the increase in the proportion of galectin-3 affects the balance from a cytosolic distribution towards
translocation into the nucleus.
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1. Introduction
The b-galactoside-binding lectin galectin-3 is a promis-
ing biomarker in a variety of distinct tumors [1]. Galec-
tin-3 is involved in many cellular processes including
apoptosis, cell growth, cell adhesion, cell differentiation
and intracellular trafficking. Moreover, expression and
subcellular distribution of galectin-3 change with cellu-
lar differentiation. An up-regulation of the expression of
galectin-3 was demonstrated for carcinomas of the
stomach, liver, pancreas, thryroid gland, ovary and blad-
der [2]. On the other hand, carcinoma of the endome-
t r i u m[ 3 ] ,m a m m a r yg l a n d[ 4 ]a n dp r o s t a t e[ 5 ]s h o wa
decrease in the expression of galectin-3. Based on these
observations, a decline or an increase of galectin-3 dur-
ing development of a certain tumor cannot be predicted
in general. Moreover, conflicting data were published
for colon carcinoma [6,7].
Here, we studied the expression as well as the distri-
bution of galectin-3 in clear cell renal cell carcinoma
(CCRCC) from 39 patients. CCRCC is the most com-
mon tumor in human kidney with a percentage of about
70%. In our study, the dedifferentiation of epithelial tis-
sue into tumor was estimated using a set of different
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of the basolateral membrane, whereas aquaporin-2 and
villin were studied as members of the apical domain of
epithelial cells.
Our data revealed a reduction of aquaporin-2, E-cad-
herin and villin in CCRCC tumor cells from 39 patients
concomitant with an increase in galectin-3 in more than
two thirds of the cases analyzed. This effect was corro-
borated by CCRCC cells in culture compared to renal
epithelial cells and is in line with RT-PCR-based data on
66 patients and CCRCC cell lines [8] or cDNA microar-
ray analysis of 4 CCRCC patients [9]. On the other
hand, a loss of galectin-3 expression in renal carcino-
genesis is described in a study with 149 patients [10], a
discrepancy that might be explained by the heteroge-
neous patient cohort which had been recruited for this
study. Two additional immunohistochemical studies of
74 [11] or 137 [12] CCRCCs revealed heterogeneous
data and conclude that the survival rate is less-favorable
in the CCRCC group with high galectin-3 expression.
These results are in agreement with our observation
that exclusively patients with high galectin-3 levels had
developed metastasis at the time of nephrectomy. On
the subcellular level, the balance of cytosolic versus
nuclear galectin-3 was shifted towards the nucleus in
CCRCC tumor tissues. Taken together, our results sug-
gest that CCRCC tumor formation is characterized by
notable synthesis of galectin-3, which is to a significant
extent translocated into the cell nucleus.
2. Methods
2.1 Antibodies
Galectin-3 was detected with rabbit polyclonal antibo-
dies essentially as described before [13]. Antibodies
directed against E-cadherin (BDBiosciences, Heidelberg,
Germany), GAPDH (Clontech, St-Germain-en-Laye,
France) aquaporin-2 (US Biological, Swampscott, Massa-
chusetts) and lactate-dehydrogenase (Abcam, Cam-
bridge, UK) were purchased. Rabbit polyclonal
antibodies against lamin A/C as well as mouse monoclo-
nal anti-galectin-3 antibodies were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-villin
a n t i b o d i e sw e r ek i n d l yp r o v i d e db yD r .S y l v i eR o b i n e
(Curie Institute, Paris). Mouse anti a- tubulin antibodies
and rabbit anti-b-catenin antibodies were purchased
from Sigma (Munich, Germany). Alexa488 and
Alexa546 secondary antibodies were purchased from
Invitrogen (Carlsbad, CA). Hoechst 33342 from Fluka
(Ronkonkoma, NY) was used for nuclei staining.
2.2 Kidney sample preparation, cell culture and Western
blotting
Renal cancer samples, intermediate tissue sample and
normal tissue samples of the same kidney were obtained
from nephrectomy surgeries. The intersection zone
between tumor and normal tissue was defined as inter-
mediate tissue. The study was positively evaluated by
the local ethic commission. The patients gave a written
informed consent for this study and were not followed
clinically. After nephrectomy the specimens were stored
in ice-cold PBS containing a protease inhibitor cocktail
and samples were immediately processed for Western
blotting, immunohistochemistry or nuclear matrix isola-
tion. Epithelial kidney cells (RC-124) and cells of clear
cell renal cell carcinoma (RCC-FG1) (Cell Lines Service,
Germany) were cultivated in McCoy’s5 am e d i u m / 1 0 %
FCS (PAA, Pasching, Austria). Western blot analysis was
performed essentially as described before [13]. Protein
concentrations were establi s h e db yB r a d f o r dp r o t e i n
assay (BioRad DC Protein Assay, Munich, Germany).
Equal amounts of 60 μg/slot were separated by SDS-
PAGE and transferred to nitrocellulose membranes.
Membranes were blocked for 1 h in 5% skimmed milk
powder in PBS. Following immunostaining, bands were
detected and quantified using Gel-Pro Software (Kapelan
Bio-Imaging, Leipzig, Germany) and normalized to the
sum or to tubulin quantities of the same sample.
2.3 Histochemistry and immunohistochemistry
Kidney samples from normal, intermediate and tumor
tissue were cut into sections of 5 mm and fixed with
either formalin (3.7%) or Carnoy (60% Ethanol, 30%
chloroform, 10% acetic acid) overnight and processed as
previously described [13]. Images of the samples were
captured using a confocal microscope TCS SP2 AOBS
(Leica, Wetzlar, Germany). Image stacks were deconvo-
luted and 3D reconstructed by using the Volocity soft-
ware package (Improvision, Coventry, UK).
2.4 Nuclear matrix isolation
Immediately following nephrectomy, nuclear matrix of
homogenized tissues was isolated essentially according
to [14]. All procedures were performed on ice and all
buffers were cooled to 4°C. Normal and tumor tissue
samples from human kidney were Dounce homogenized
in 2 ml of buffer A (0.25 M sucrose, 20 mM Tris-HCl, 3
mM MgCl2, pH 7.85 supplemented with a protease
inhibitor cocktail) followed by centrifugation at 1000 ×
g for 10 min at 4°C. The supernatants (cytosolic pro-
teins) were collected. Pellets were washed twice in buffer
A with 5% Triton X-100 and centrifuged each time. The
final pellets were resuspended in 400 μlo fb u f f e rB
(0.25 M sucrose, 20 mM Tris-HCl, 3 mM MgCl2,0 . 4M
KCl, 5 mM DTT, pH 7.85) with 20% glycerol. Protein
samples containing 40 μg/lane were separated by SDS-
PAGE and transferred to nitrocellulose.
Densitometric quantification of each band was per-
formed using Gel-Pro Software (Kapelan Bio-Imaging,
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nuclei of tumor tissue relative to the amount of galec-
tin-3 in nuclei of normal kidney tissue was calculated.
2.5 Statistical analysis
Statistical analysis was performed using the Graph Pad
Prism 5 software package (Graph Pad software, La Jolla,
CA). The levels of each protein in cancer and in normal
kidney tissue were expressed in scatter-plots, including
means, as the ratio of the protein normalized to the
sum of normal and tumor tissue. In this case densito-
metric values of normal or tumor tissues from each
p a t i e n tw e r ed i v i d e db yt h es u mo fb o t h .T h er e s u l t s
were statistically analyzed using Student’st - t e s t .P<
0.001 was considered significant.
3. Results and discussion
3.1 Histological analysis of normal, intermediate or tumor
tissues
For a histological evaluation of tissue samples from 39
CCRCC patients different sections of excised kidneys
were fixed and stained with azan or hematoxylin/eosin
(Figure 1). Here, kidney sections of either normal, inter-
mediate or tumor tissue were analyzed. Sections from
the renal cortex are characterized by a frequent occur-
rence of glomeruli (Figure 1A and 1D). Epithelial cells
of the proximal tubules feature microvilli on the apical
surface, which leads to a diffuse appearance of the
luminal side. In contrast, epithelial cells of the distal
tubule are missing the brush border leading to a defined
luminal cell border. Collecting ducts, on the other hand,
have a larger diameter and like the distal tubule do not
have a brush border on the luminal part of the tubule.
This well organized and clearly defined structure is
absent in tumor tissue. Figure 1B and 1E depict transi-
tions between normal and tumor tissue. CCRCC sec-
tions are shown in Figure 1C and 1F. This kind of
tumor is known to grow as a solid tumor with neoplas-
tic cells enriched in cytoplasmic glycogen and lipids,
which provokes the clear appearance of tumor cells [15].
Collagen fibers are emphasized in the azan stained sam-
ples (Figure 1D-F). The distribution of these extracellu-
lar fibers, changes due to the conversion of a well-
organized kidney structure into the spreading tumor
(Figure 1E). Altogether, the histological appearance of
CCRCC-samples used in our study corresponds to typi-
cal characteristics already described before [16].
3.2 Increased levels of galectin-3 in CCRCC-tumor tissues
To monitor the expression pattern of galectin-3, equal
protein amounts of tissue homogenates from normal,
intermediate or tumor were analyzed by immunoblots
together with the polypeptides GAPDH or a-tubulin
and epithelial b-catenin, E-cadherin and villin. Most of
the immunoblots showed an increase in galectin-3 stain-
ing in tumor versus normal samples (Figure 2A), while
Figure 1 Representative images of hematoxylin & eosin (HE) and azan stained human kidney tissue sections. A-C, H&E-stained kidney
sections. D-F, Azan-stained kidney sections. A and D show the renal cortex of normal kidney tissue. B and E present kidney sections with areas of
healthy tissue and clear cell renal cell carcinoma (intermediate kidney tissue). C and F show sections of CCRCC. Mc: Malpighian corpuscle, dt: distal
tubule, pt: proximal tubule, cd: collecting duct, bv: blood vessel, tt: tumor tissue, nt: normal tissue. Scale bars: 300 μm, scale bars inset: 150 μm.
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Page 3 of 10Figure 2 Immunoblot analysis of galectin-3, E-cadherin, and villin in normal kidney, intermediate and tumor tissues as well as RC-124
and RCC-FG1 cells. A, Protein contents in homogenates from tissue samples of 39 patients were measured. Equal protein amounts were
separated by SDS-PAGE followed by immunoblot analysis with anti-galectin-3, -E-cadherin or -villin. One representative blot is depicted. B,
Quantitative immunoblot analysis of galectin-3, villin and E-cadherin in normal and tumor tissue. C, Relative variation of galectin-3, villin and E-
cadherin in CCRCC to the corresponding normal tissue of each patient. D, Immunoblot analysis of galectin-3, E-cadherin and GAPDH in the
lysates of epithelial cells from human kidney (RC-124) in comparison to the clear cell renal cell carcinoma cell line (RCC-FG1) E, Quantification of
3 individual experiments.
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Page 4 of 10the intensities of E-cadherin and villin were decreased in
the tumor. The staining of galectin-3, E-cadherin or vil-
lin in the intermediate tissues fluctuates between the
basic values for normal or tumor tissues. For densito-
metric quantificatio nt h es u i t a b i l i t yo fa-tubulin as a
reference protein in comparison to b-catenin or
GAPDH was assessed (additional file 1A). In agreement
with published data CCRCC tumor tissues revealed
reduced mean values of b-catenin [17], whereas the
amount of GAPDH was increased [18]. For a-tubulin
no tendency between normal and tumor tissues could
be observed. Therefore, a- t u b u l i nw a su s e da sar e f e r -
ence protein for normalization of the densitometric data
from galectin-3, E-cadherin, or villin in additional file
1B. Furthermore, the data were normalized to the sum
(Figure 2B, C). Both calculations demonstrated an
increase in galectin-3 and a decrease in E-cadherin or
villin in most of the tumor samples with p-values below
0,001 according to Student’s T-test. To conclude, galec-
tin-3 expression was significantly increased in a majority
of 79% of the CCRCC-patients during tumor develop-
ment. As summarized in Table 1, clinicopathological
parameters, including age, sex, histological grade and
metastasis, were well balanced between the groups.
However, none of the patients with low galectin-3 levels
had developed metastases at the time of nephrectomy,
thus pointing to a correlation between galectin-3 expres-
sion and tumor malignancy as had been recently pub-
lished for gastric cancer [19,20].
We further estimated the expression patterns of E-cad-
herin and galectin-3 in a cell culture model. When kidney,
non-CCRCC human RC-124 cells were compared with
the tumorigenic cell line RCC-FG1, E-cadherin levels in
the RCC cell line were clearly below the amount of normal
cells, whereas the expression of galectin-3 in these cells
was dramatically increased (Figure 2D, E). These data con-
firmed our impression of a general increase of galectin-3
expression in tumorigenic CCRCC tissues.
3.3 Renal cells of the collecting duct and distal tubule
express galectin-3
Next, we addressed the question if the observed changes
in the expression level of galectin-3 during tumor devel-
opment were accompanied by a shift in the subcellular
distribution of the lectin. Therefore, the cellular localiza-
tion of galectin-3 was investigated by immunohisto-
chemistry in comparison with endogenous polarity
markers. In solid tumors, like CCRCC, cells are dediffer-
entiated and tumor cells have lost the characteristic
polarized structure of epithelial cells. In the present
study, apical aquaporin-2 or villin and basolateral E-cad-
herin were used. Figure 3 shows typical confocal fluores-
cence images of normal and tumor sections, in which
the polarity markers (green), galectin-3 (red) and the
nucleus (blue) were immunostained. Aquaporin-2 is
concentrated in the apical domain of collecting duct
principal cells [21] (Figure 3A). In contrast, actin-asso-
ciated villin was exclusively found in microvilli of proxi-
mal tubule cells [22] (Figure 3C). Basolateral E-cadherin
can be detected in cells of the collecting duct and distal
tubule [23] (Figure 3E). Galectin-3 is expressed exclu-
sively in epithelial cells of the collecting duct and the
distal tubule, which are positive for E-cadherin but
negative for villin (Figure 3A, C, E). Not all cells lining
collecting ducts or distal tubules revealed representative
amounts of the lectin leading to a mosaic expression
pattern of galectin-3. Cells expressing galectin-3 accu-
mulated the lectin mainly in the cytosol and were in
most cases aquaporin-negative. In contrast, CCRCC
tumor cells showed a completely different morphology
characterized by a disordered arrangement of cells with
irregular shape (Figure 3B, D, F). In conjunction with
the biochemical data presented in Figure 2, villin and E-
cadherin were dramatically decreased in the tumor tis-
sues. This decline in expression was also detected for
apical aquaporin-2 in CCRCC tumor cells (Figure 3B).
Galectin-3, on the other hand, could be well detected in
the cytosol as well as in nuclei of most of the non-polar
tumor cells.
Table 1 Clinicopathological characteristics of the study
population according to galectin-3 expression
Parameters High galectin-3
No. of cases (%)
Low galectin-3
No. of cases (%)
Age
≤ 60 4 (12.9) 3 (37.5)
> 60 27 (87.1) 5 (62.5)
Gender/Sex
Male 14 (45.2) 3 (37.5)
Female 17 (54.8) 5 (62.5)
Clinical stage
I 12 (38.7) 4 (50.0)
II 6 (19.4) 0
III 11 (35.5) 4 (50.0)
IV 2 (6.4) 0
Histologic grade
G1 2 (6.4) 0
G2 22 (71.0) 7 (87.5)
G3 7 (22.6) 1 (12.5)
Metastasis
M0 20 (64.5) 8 (100)
M1 11 (35.5) 0
n3 1 8
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Page 5 of 10Figure 3 Confocal fluorescence images showing the distribution of galectin-3 and different polarity markers in normal kidney and
tissue from clear cell renal cell carcinoma. All sections were immunostained against apical aquaporin-2 (AQP-2) and villin or basolateral E-
cadherin. In all fluorescence images the polarity markers are indicated in green, galectin-3 is depicted in red and the nuclei are stained with
Hoechst 33342 (blue). In normal kidney sections aquaporin-2 is concentrated on the apical domain of epithelial cells of the collecting duct,
whereas villin is part of the brush border of the proximal tubule. E-cadherin can be detected in cells of the distal tubule and the collecting duct.
Arrows mark the apical localization of AQP-2 and villin (A, C) or the basolateral localization of E-cadherin (E). In all tissue sections of the tumor
the expression of the polarity markers is reduced or completely lost. In normal kidney areas, galectin-3 is found in the collecting duct as well as
in the distal tubule, but not in the proximal tubule. Stars depict single cells, in which galectin-3 is expressed. Scale bars: 25 μm.
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Page 6 of 103.4 Nuclear accumulation of galectin-3 in CCRCC tumor
cells
To determine if galectin-3 was enriched in the nuclei of
tumor cells, we recorded the fluorescence of galectin-3
staining in image stacks of whole cells in normal as well
as in CCRCC tumor tissues. This approach verifies that
the whole fluorescence of a cell is registered and
excludes misinterpretations due to fluorescence detec-
tion restricted to a single focal plane. The 3D-recon-
structions depicted in Figure 4A show a concentration
of galectin-3 in the Hoechst-stained cell nuclei of tumor
cells, whereas the lectin was mainly distributed in the
cytosol of normal renal epithelial cells.
We addressed this point after we had screened the
first 30 patients of the study by purification of nuclei
from sample material from nine patients. The purity of
our isolation protocol was verified by immunoblot with
nuclear lamin and cytosolic lactate dehydrogenase
(LDH) (Figure 4B). A representative immunoblot of the
galectin-3 distribution in nuclear and cytosolic fractions
Figure 4 Nuclear localization of galectin-3 in normal and tumor tissue samples. A. Immunofluorescence of galectin-3 and nuclear Hoechst
was recorded in different layers of normal and CCRCC tissues. The recorded image stacks were processed by deconvolution and background
elimination. Dual colors are depicted in the 3D-reconstructed images. On the left galectin-3 (red) is shown; nuclei are depicted in blue. Images
without nuclear staining are depicted on the right. Scale bars: 15 μm. B. Immunoblots of nuclear lamin and LDH in isolated nuclei or cytosolic
fractions. C. Imunoblots of galectin-3 or lamin in nuclear or cytosolic fractions from normal or tumor tissue. D. Relative changes in nuclear versus
cytosolic localization as quantified from 9 immunoblots from normal or CCRCC tissues are depicted.
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Page 7 of 10is depicted in Figure 4C. In six out of nine patients we
observed an obvious accumulation of galectin-3 in the
nuclei of tumor cells (Figure 4D). This suggests that in
the majority of CCRCC tumors analyzed, the cells
enhance galectin-3 levels and concurrently recruit pre-
dominant amounts of this lectin into the nucleus. Such
an increase in nuclear translocation points to a change
in the balance of nuclear import/export.
4. Conclusions
Changes in the expression of galectin-3 are heterogeneous
and depend on tumor origin as well as on the tissue
affected [24]. Moreover, even if we focus on published
data of CCRCC tumor patients the spectrum reaches from
an increase in galectin-3 levels in tumors [8,9,11,12] to
reduced amounts of the lectin following tumorigenesis
[10]. In our study we used normalized immunoblots in
combination with immunofluorescence microscopy. Even
if one considers the relatively low number of samples ana-
lyzed, our data revealed a significant reduction of E-cad-
herin, a classical marker known to be reduced in CCRCC
[25], which can be regarded as a positive study control.
However, in conjunction with data received from a micro-
array analysis [9] the expression pattern of galectin-3 in
CCRCC is heterogeneous. A decrease in galectin-3 was
observed in about 20% of the tumors. Nevertheless, the
intensive galectin-3 labeling in the majority of samples and
the strong expression in RCC-FG1 cells suggests that this
lectin is involved in cancer progression and cellular differ-
entiation. In this context, it is possibly clinically significant
that in agreement with the data of Sakaki et al.[ 8 ]w e
observed a reduced tendency of metastasis in patients with
low galectin-3. This can be explained by previous studies,
which showed that gal-3 expression is correlated with cell
motility in several cancers, and suggested that gal-3 inhib-
ited cell-cell and cell-ECM interactions [26,27]. In pan-
creatic cancer, this is linked to Akt-regulation by galectin-
3, which in turn modulates GSK-3b phosphorylation and
b-catenin degradation by suppression of the b-catenin/
Wnt signaling pathway [20]. For renal cell carcinoma a
putative involvement of galectin-3 in this pathway is evi-
denced by reduced b-catenin levels detected in this as well
as in prior studies [17].
Histologically, the observed mosaic pattern of galectin-
3 expression in the collecting duct is in agreement with
the description of the lectin in a-intercalated cells in
adult kidneys [28]. This would also explain the dimin-
ished appearance of galectin-3 in aquaporin-2-positive
capital cells [21]. If we now compare the distinct renal
epithelial tissues, galectin-3 synthesis is restricted to
epithelial cells of the distal tubules and the collecting
ducts. In view of the notion that virtually all CCRCC
are derived from the proximal tubule [29] this implies
that proximal tubular cells would dramatically increase
galectin-3 synthesis during tumorigenesis. A similar
property was observed for the Wilms tumor suppressor
gene, which is not expressed in proximal tubular cells
but synthesized in primary RCC tumor samples [30]. On
t h eo t h e rh a n d ,C C R C C sw i t ha no r i g i ni nt h ed i s t a l
tubules are also plausible [31]. Then, variations in the
cellular origin of the tumor would explain the diverse
galectin-3 expression patterns in various CCRCC cases.
Another question is why galectin-3 could not be
detected in the proximal tubules. Based on our previous
observations, this lectin serves as a sorting receptor of
endosomal organelles and recruits newly synthesized
non-raft associated glycoproteins into transport vesicles
destined for the apical cell surface [32,33]. This function
is necessary for the maintenance of apical surface trans-
port and therefore epithelial cell polarity. However, since
the repertoire of galectins in renal cells is manifold [34],
another member of the galectin family might replace
galectin-3 in the proximal tubules. It is also plausible that
non-raft dependent apical trafficking is a minor pathway
in this part of the nephron and becomes predominant in
distal tubules. The presence of galectin-3 in secretory
organelles would thus confirm the integrity of epithelial
cells lining distal tubules and collecting ducts.
In CCRCC tissues the increase in expression is paral-
leled by a rise in the amount of nuclear galectin-3. Shut-
tling of the lectin between the cytosol has been reported
to depend on the cell type, the context of the cells and the
tissue analyzed [35]. Translocation of galectin-3 into the
nucleus may induce apoptosis and therefore defeat cancer
cells [36]. In addition, the lectin affects cellular differentia-
tion once exported from the nucleus. Cytosolic galectin-3
is required for ciliogenesis of the primary cilium [13],
which is involved in epithelial morphogenesis. Moreover,
as indicated above it enters endosomal organelles for api-
cal protein sorting. Evidence of a nuclear accumulation of
galectin-3 thus suggests that a role within this cellular
compartment prevails in CCRCC. The question, whether
this is the cause or the result of tumor development,
remains to be solved in future studies.
Additional material
Additional file 1: Immunoblot analysis of b-catenin, E-cadherin,
GAPDH, galectin-3, a-tubulin and villin in normal kidney and tumor
tissues. A, Quantitative immunoblot analysis of b-catenin, GAPDH and a-
tubulin normalized to the sum in normal and tumor tissue from 39
patients. B, Immunoblot analysis of galectin-3, E-cadherin and villin
normalized to the corresponding a-tubulin quantities. The results were
analyzed using Student’s t-test. P < 0.001 was considered significant.
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